ADDED
As of March 13, 2026 , the registrant had 38,176,089 and 967,759 shares of Class A and B common stock, $0.0001 par value per share, outstanding, respectively.
Form 10-K Summary 131 Signatures 132 Sera, PreTRM, PreTRM Global, The Pregnancy Company, Sera Prognostics, LikeMine, and our logo are our trademarks.
Our vision is to become the global leader in high-value women s health diagnostics.
We plan to do this by taking a holistic approach to providing pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother s pregnancy journey, improve maternal and neonatal health, and reduce health care costs.
The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history.
Preterm birth causes numerous medical issues requiring more time spent in the hospital, increases in pediatric care and can cause lifelong health complications, and is estimated to contribute to approximately 34% of newborn deaths.
Critically, identifying patients at higher risk of preterm birth is a clinical challenge where traditional screening methods fail to identify 81% of spontaneous singleton preterm births, and at least 50% of pregnant women who deliver prematurely had no known risk factors, limiting the opportunity to receive any personalized treatments or interventions that could potentially improve this outcome.
According to the American College of Obstetricians and Gynecologists, or ACOG, an effective treatment to reduce preterm birth should be available, and the screening program should be feasible, cost effective, and accessible to all patients.
In many cases, the complications of preterm birth have profound short- and long-term health consequences for the mother and baby.
Beyond the unmet clinical need, the economic consequences of preterm birth are estimated to be approximately $25 billion annually in the United States.
REMOVED
As of March 14, 2025, the registrant had 36,695,803 and 967,759 shares of Class A and B common stock, $0.0001 par value per share, outstanding, respectively.
Form 10-K Summary 129 Signatures 130 Sera, PreTRM, The Pregnancy Company and our logo are our trademarks.
Our vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother s pregnancy journey, improve maternal and neonatal health, and reduce health care costs.
In many cases these complications have profound short- and long-term health consequences for the mother and baby.
These health consequences of preterm birth alone are estimated to be approximately $25 billion annually in the United States.
We have built an advanced, proprietary, and scalable proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are highly accurate predictors of dynamic changes that occur during pregnancy.
By incorporating our proprietary technology platform into our rigorous data-driven development process, we have created a differentiated approach for effectively addressing major milestones, conditions, and features of pregnancy.
We believe our large and growing pregnancy dataset (clinical, demographic, and proteomic) is a substantial asset for understanding pregnancy complications, health inequities, and the personal pregnancy journey.
We envision that our comprehensive approach will enable us to fully characterize one of the most important periods in the lives of women and their babies, and will help to improve the well-being of each.
Our first commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth.